Trial Profile

A Randomized, Double-blind, Multi-center Phase III Clinical Study to Assess the Efficacy and Safety of Surufatinib Compared to Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 03 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

29 Mar 2023 Status changed from active, no longer recruiting to completed.
13 Sep 2022 Results from NCT02267967, NCT02588170, NCT02589821; assessing whether radiomics-based machine learning model could predict treatment responses in patients with advanced NET, presented at the 47th European Society for Medical Oncology Congress
07 Jun 2022 Results of pooled analysis of two studies ( SANET-p and SANET-ep) assessing surufatinib safety , presented at the 58th Annual Meeting of the American Society of Clinical Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com